Quinazoline derivatives

Abstract

The present invention concerns the compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein Z represents NH; Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 3-7 alkyl-CO—NH optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino- or C 1-4 alkyloxycarbonylamino-, C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-5 alkyl-CO NR 15 —C 1-5 alkyl-, —C 1-3 alkyl-NH—CO-Het 20 -, —C 1-2 alkyl-CO-Het 21 -CO—, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, or —NR 22 —CO—C 1-3 alkyl-NH—; X 1 represents a direct bond, O or —O—C 1-2 alkyl-; X 2 represents a direct bond, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl-, —O—N═CH— or —C 1-2 alkyl-; R 1 and R 2 each independently represents hydrogen or halo; R 3 represents hydrogen; R 4 represents hydrogen or C 1-4 alkyloxy; R 12 and R 13 each independently represents hydrogen or C 1-4 alkyl; R 14 and R 15 represents hydrogen; R 16 and R 17 each independently represent hydrogen or C 1-4 alkyl; R 18 and R 19 each independently represent hydrogen or C 1-4 alkyl optionally substituted with phenyl or hydroxy; R 20 and R 21 each independently represent hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkyloxy; Het 20 , Het 21 and Het 22 each independently represent a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy.

1 . A compound having the formula 
       
         
           
           
               
               
           
         
       
       the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
 Z represents O, CH 2 , NH or S; in particular Z represents NH; 
 Y represents —C 3-9 alkyl-, —C 3-9 alkenyl-, —C 3-9 alkynyl-, —C 3-7 alkyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-,
 —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, 
 —C 3-7 alkynyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 1-5 alkyl-oxy-C 1-5 alkyl-, —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, 
 —C 1-5 alkyl-CO—NR 15 —C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-6 alkyl-NH—CO—, 
 —C 1-3 alkyl-NH—CS-Het 20 -, —C 1-3 alkyl-NH—CO-Het 20 -, C 1-2 alkyl-CO-Het 21 -CO—, 
 -Het 22 -CH 2 —CO—NH—C 1-3 alkyl-, —CO—NH—C 1-6 alkyl-, —NH—CO—C 1-6 alkyl-, 
 —CO—C 1-7 alkyl-, —C 1-7 alkyl-CO—, —C 1-6 alkyl-CO—C 1-6 alkyl-, 
 —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, 
 —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, —C 1-2 alkyl-NR 21 —CH 2 —CO—NH—C 1-3 alkyl-, or 
 —NR 22 —CO—C 1-3 alkyl-NH—; 
 
 X 1  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 11 ,
 —NR 11 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 ,
 —NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 R 1  represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl-,
 halo-phenyl-carbonylamino-, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo; 
 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-,
 C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl-, C 2-6 alkynyl-, C 3-6 cycloalkyl-, 
 C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 , 
 C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-; 
 
 R 3  represents hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with one or more substituents selected from halo, C 1-4 alkyloxy-, amino-, mono- or di(C 1-4 alkyl)amino-,
 C 1-4 alkyl-sulfonyl- or phenyl; 
 
 R 4  represents hydrogen, hydroxy, Ar 3 -oxy, Ar 4 —C 1-4 alkyloxy-, C 1-4 alkyloxy-,
 C 2-4 alkenyloxy- optionally substituted with Het 12  or R 4  represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy-, hydroxy, halo, Het 2 -, —NR 7 R 8 , -carbonyl-NR 9 R 10  or Het 3 -carbonyl-; 
 
 R 5  and R 6  are each independently selected from hydrogen or C 1-4 alkyl; 
 R 7  and R 8  are each independently selected from hydrogen, C 1-4 alkyl, Het 8 ,
 aminosulfonyl-, mono- or di (C 1-4 alkyl)-aminosulfonyl, hydroxy-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl-, hydroxycarbonyl-C 1-4 alkyl-, C 3-6 cycloalkyl, 
 Het 9 -carbonyl-C 1-4 alkyl-, Het 10 -carbonyl-, polyhydroxy-C 1-4 alkyl-, Het 11 -C 1-4 alkyl- or Ar 2 —C 1-4 alkyl-; 
 
 R 9  and R 10  are each independently selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl,
 Het 4 , hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
 R 11  represents hydrogen, C 1-4 alkyl, Het 5 , Het 6 -C 1-4 alkyl-, C 2-4 alkenylcarbonyl-optionally substituted with Het 7 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-,
 C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 12  represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 18 -C 1-4 alkyl-,
 phenyl-C 1-4 alkyl-oxy-carbonyl-, Het 17 , C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or R 12  represents phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 13  represents hydrogen, C 1-4 alkyl, Het 13 , Het 14 -C 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 R 14  and R 15  are each independently selected from hydrogen, C 1-4 alkyl, Het 15 -C 1-4 alkyl- or C 1-4 alkyloxyC 1-4 alkyl-; 
 R 16  and R 17  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 18  and R 19  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 20  and R 22  each independently represents hydrogen or C 1-4 alkyl optionally substituted with hydroxy or C 1-4 alkyloxy; 
 R 21  represents hydrogen, C 1-4 alkyl, Het 23 -C 1-4 alkylcarbonyl- or
 R 21  represents mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-carbonyl- optionally substituted with hydroxy, pyrimidinyl, dimethylamine or C 1-4 alkyloxy; 
 
 Het 1  represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1  is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 
 Het 2  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 2  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-, mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-, aminoC 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-sulfonyl-, aminosulfonyl-; 
 
 Het 3 , Het 4  and Het 8  each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl,
 oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 3 , Het 4  or Het 8  is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C 1-4 alkyl-, 
 C 3-6 cycloalkyl-C 1-4 alkyl-, aminosulfonyl-, mono- or di(C 1-4 alkyl)aminosulfonyl or amino-C 1-4 alkyl-; 
 
 Het 5  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 Het 6  and Het 7  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 9  and Het 10  each independently represent a heterocycle selected from furanyl,
 piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, 
 imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 9  or Het 10  is optionally substituted C 1-4 alkyl, C 3-6 cycloalkyl-C 1-4 alkyl- or amino-C 1-4 alkyl-; 
 
 Het 11  represents a heterocycle selected from indolyl or 
 
       
         
           
           
               
               
           
         
         Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino- or mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-; 
 
         Het 13  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 14  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Het 15  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Het 16  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl; and 
 
         Het 17  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 18  and Het 19  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, 
 hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Het 20 , Het 21  and Het 22  each independently represent a heterocycle selected from pyrrolidinyl, 2-pyrrolidinonyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from hydroxy,
 C 1-4 alkyl, hydroxy-C 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
         Het 23  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Ar 1 , Ar 2 , Ar 3 , Ar 4  and Ar 5  each independently represent phenyl optionally substituted with cyano, C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-,
 hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl. 
 
       
     
     
         2 . A compound according to  claim 1  wherein;
 Z represents O, NH or S; 
 Y represents —C 3-9 alkyl-, —C 3-9 alkenyl-, —C 1-5 alkyl-oxy-C 1-5 alkyl-,
 —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, 
 —C 1-5 alkyl-CO—NR 15 —C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-6 alkyl-NH—CO—, 
 —CO—NH—C 1-6 alkyl-, —NH—CO—C 1-6 alkyl-, —CO—C 1-7 alkyl-, —C 1-7 alkyl-CO—, 
 —C 1-6 alkyl-CO—C 1-6 alkyl-, —C 1-2 alkyl-NH—CO—CH 2 R 16 —NH—; 
 
 X 1  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 11 ,
 —NR 11 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 ,
 NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 R 1  represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl,
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo; 
 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-,
 C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl-, C 2-6 alkynyl-, C 3-6 cycloalkyl-, 
 C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 , 
 C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-; 
 
 R 3  represents hydrogen, C 1-4 alkyl or C 1-4 alkyl substituted with one or more substituents selected from halo, C 1-4 alkyloxy-, amino-, mono- or di(C 1-4 alkyl)amino-,
 C 1-4 alkyl-sulfonyl- or phenyl; 
 
 R 4  represents hydrogen, hydroxy, Ar 3 -oxy, Ar 4 —C 1-4 alkyloxy-, C 1-4 alkyloxy-,
 C 2-4 alkenyloxy- optionally substituted with Het 12  or R 4  represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy-, hydroxy, halo, Het 2 -, —NR 7 R 8 , -carbonyl-NR 9 R 10  or Het 3 -carbonyl-; 
 
 R 5  and R 6  are each independently selected from hydrogen or C 1-4 alkyl; 
 R 7  and R 8  are each independently selected from hydrogen, C 1-4 alkyl, Het 8 ,
 aminosulfonyl-, mono- or di (C 1-4 alkyl)-aminosulfonyl, hydroxy-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl-, hydroxycarbonyl-C 1-4 alkyl-, C 3-6 cycloalkyl, 
 Het 9 -carbonyl-C 1-4 alkyl-, Het 10 -carbonyl-, polyhydroxy-C 1-4 alkyl-, Het 11 -C 1-4 alkyl- or Ar 2 —C 1-4 alkyl-; 
 
 R 9  and R 10  are each independently selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl,
 Het 4 , hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
 R 11  represents hydrogen, C 1-4 alkyl, Het 5 , Het 6 -C 1-4 alkyl-, C 2-4 alkenylcarbonyl-optionally substituted with Het 7 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-,
 C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 12  represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 17 , Het 18 -C 1-4 alkyl-,
 C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, 
 C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, 
 amino or C 1-4 alkyloxy-; 
 
 R 13  represents hydrogen, C 1-4 alkyl, Het 13 , Het 14 -C 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 R 14  and R 15  are each independently selected from hydrogen, C 1-4 alkyl, Het 15 -C 1-4 alkyl- or C 1-4 alkyloxyC 1-4 alkyl-; 
 R 16  represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl,
 methylsulfide, hydroxy, thiol, hydroxyphenyl, aminocarbonyl, hydroxycarbonyl, 
 amine, imidazoyl or guanidino; 
 
 Het 1  represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1  is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 
 Het 2  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 2  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-, mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-, aminoC 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-sulfonyl-, aminosulfonyl-; 
 
 Het 3 , Het 4  and Het 8  each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl,
 oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 3 , Het 4  or Het 8  is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C 1-4 alkyl-, 
 C 3-6 cycloalkyl-C 1-4 alkyl-, aminosulfonyl-, mono- or di(C 1-4 alkyl)aminosulfonyl or amino-C 1-4 alkyl-; 
 
 Het 5  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 Het 6  and Het 7  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 9  and Het 10  each independently represent a heterocycle selected from furanyl,
 piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, 
 imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 9  or Het 10  is optionally substituted C 1-4 alkyl, C 3-6 cycloalkyl-C 1-4 alkyl- or amino-C 1-4 alkyl-; 
 
 Het 11  represents a heterocycle selected from indolyl or 
 
       
         
           
           
               
               
           
         
         Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino- or mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-; 
 
         Het 13  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 14  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-, 
         C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 15  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, 
         C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 16  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl; and 
 
         Het 17  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 18  and Het 19  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, 
 hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Ar 1 , Ar 2 , Ar 3 , Ar 4  and Ar 5  each independently represent phenyl optionally substituted with cyano, C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-,
 hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl. 
 
       
     
     
         3 . A compound according to  claim 1  or  2  wherein;
 Z represents NH; 
 Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 1-5 alkyl-oxy-C 1-5 alkyl-,
 —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-NH—CO—, 
 —NH—CO—C 1-6 alkyl-, —CO—C 1-7 alkyl-, —C 1-7 alkyl-CO—, C 1-6 alkyl-CO—C 1-6 alkyl, 
 —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, 
 —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, —C 1-2 alkyl-NR 21 —CH 2 —CO—NH—C 1-3 alkyl-, 
 —NR 22 —CO—C 1-3 alkyl-NH—, —C 1-3 alkyl-NH—CO-Het 20 -, C 1-2 alkyl-CO-Het 21 -CO—, or 
 -Het 22 -CH 2 —CO—NH—C 1-3 alkyl-; 
 
 X 1  represents O, —O—C 1-2 alkyl-, —O—N═CH—, NR 11  or —NR 11 —C 1-2 alkyl-; 
 X 2  represents a direct bond, —C 1-2 alkyl-, O, —O—C 1-2 alkyl-, —O—N═CH—, NR 12  or NR 12 —C 1-2 alkyl-; 
 R 1  represents hydrogen, cyano, halo or hydroxy; 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
 C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl-, C 1-4 alkyl-, C 2-6 alkynyl-, Ar 5  or Het 1 ; 
 
 R 3  represents hydrogen; 
 R 4  represents hydrogen, hydroxy, C 1-4 alkyloxy- or R 4  represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; 
 R 12  represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; 
 R 13  represents hydrogen or Het 14 -C 1-4 alkyl; 
 R 14  and R 15  represent hydrogen; 
 R 16  represents hydrogen or C 1-4 alkyl substituted with hydroxy; 
 R 17  represents hydrogen or C 1-4 alkyl, in particular hydrogen or methyl; 
 R 18  represents hydrogen or C 1-4 alkyl optionally substituted with hydroxy or phenyl; 
 R 19  represents hydrogen or C 1-4 alkyl; 
 R 20  represents hydrogen or C 1-4 alkyl; 
 R 21  represents hydrogen, C 1-4 alkyl, Het 23 -C 1-4 alkylcarbonyl- or
 R 21  represents mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-carbonyl- optionally substituted with hydroxy, pyrimidinyl, dimethylamine or C 1-4 alkyloxy; 
 
 R 22  represents hydrogen or C 1-4 alkyl optionally substituted with hydroxy or C 1-4 alkyloxy; 
 Het 1  represents thiazolyl optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 Het 2  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 2  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 3  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 3  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 16  represents a heterocycle selected from piperidinyl or pyrrolidinyl; 
 Het 20  represents pyrrolidinyl, 2-pyrrolidinonyl, piperidinyl or hydroxy-pyrrolidinyl,
 preferably pyrrolidinyl or hydroxy-pyrrolidinyl; 
 
 Het 21  represents pyrrolidinyl or hydroxy-pyrrolidinyl; 
 Het 22  represents pyrrolidinyl, piperazinyl or piperidinyl. 
 
     
     
         4 . A compound according to  claim 1  or  2  wherein;
 Z represents NH; 
 Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 1-5 alkyl-oxy-C 1-5 alkyl-,
 —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-6 alkyl-NH—CO—, —CO—C 1-7 alkyl-, —C 1-7 alkyl-CO— or 
 C 1-6 alkyl-CO—C 1-6 alkyl; 
 
 X 1  represents O, —O—C 1-2 alkyl-, —O—N═CH—, NR 11  or —NR 11 —C 1-2 alkyl-; 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, —O—N═CH—, NR 12  or NR 12 —C 1-2 alkyl-; 
 R 1  represents hydrogen, cyano, halo or hydroxy, preferably halo; 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-,
 C 1-4 alkyloxycarbonyl-, Het 16 -carbonyl-, C 2-6 alkynyl-, Ar 5  or Het 1 ; 
 
 R 3  represents hydrogen; 
 R 4  represents hydroxy, C 1-4 alkyloxy- or R 4  represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; 
 R 12  represents hydrogen, C 1-4 alkyl- or C 1-4 alkyl-oxy-carbonyl-; 
 R 13  represents Het 14 -C 1-4 alkyl; 
 Het 1  represents thiazolyl optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 Het 2  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 2  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 3  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 3  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 16  represents a heterocycle selected from piperidinyl or pyrrolidinyl. 
 
     
     
         5 . A compound according to  claim 1  wherein;
 Z represents NH; 
 Y represents —C 3-9 alkyl-, —CO—C 1-7 alkyl- or —C 1-7 alkyl-CO—; 
 X 1  represents —NR 11 —, —O— or —O—CH 2 —; 
 X 2  represents a direct bond, —O— or —O—CH 2 —; 
 R 1  represents halo; 
 R 2  represents hydrogen, cyano, halo, hydroxy or C 2-6 alkynyl-; 
 R 3  represents hydrogen; 
 R 4  represents C 1-4 alkyloxy substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy- or Het 2 -; 
 R 12  represents C 1-4 alkyl or R 12  represents C 1-4 alkyl-oxy-carbonyl; 
 Het 2  represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C 1-4 alkyl-; 
 Het 3  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 3  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-; 
 Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl or pyrrolidinyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, amino or C 1-4 alkyl-. 
 
     
     
         6 . A compound according to  claim 1  wherein;
 Z represents NH; 
 Y represents —C 3-9 alkyl-, —C 2-9 alkenyl-, —C 3-7 alkyl-CO—NH optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-,
 —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino- or C 1-4 alkyloxycarbonylamino-, 
 C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, 
 —C 1-5 alkyl-CO NR 15 —C 1-5 alkyl-, —C 1-3 alkyl-NH—CO-Het 20 -, 
 —C 1-2 alkyl-CO-Het 21 -CO—, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, 
 —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, or 
 —NR 22 —CO—C 1-3 alkyl-NH—; 
 
 X 1  represents a direct bond, O or —O—C 1-2 alkyl-; 
 X 2  represents a direct bond, —CO—C 1-2 alkyl-, NR 12 , —NR 12 —C 1-2 alkyl-, —O—N═CH— or —C 1-2 alkyl-; 
 R 1  represents hydrogen or halo; 
 R 2  represents hydrogen or halo; 
 R 3  represents hydrogen; 
 R 4  represents hydrogen or C 1-4 alkyloxy; 
 R 12  represents hydrogen or C 1-4 alkyl; 
 R 13  represents hydrogen or C 1-4 alkyl; 
 R 14  represents hydrogen; 
 R 15  represents hydrogen; 
 R 16  and R 17  each independently represent hydrogen or C 1-4 alkyl; 
 R 18  and R 19  each independently represent hydrogen or C 1-4 alkyl optionally substituted with phenyl or hydroxy; 
 R 20  and R 21  each independently represent hydrogen or C 1-4 alkyl optionally substituted with C 1-4 alkyloxy; 
 Het 20 , Het 21  and Het 22  each independently represent a heterocycle selected from the group consisting pyrrolidinyl, 2-pyrrolidinonyl or piperidinyl optionally substituted with hydroxy. 
 
     
     
         7 . A compound according to formula (I) wherein said compound is selected from the group consisting of;
 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclopentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-chloro-8,9,10,11,13,14,16,21-octahydro-22-methoxy-13-(2-methylpropyl)-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,10,13]benzoxatriazacycloheptadecine-12,15-dione, 19-chloro-8,9,10,11,13,14,16,21-octahydro-22-methoxy-,   4,6-ethanediylidenepyrimido[4,5-b]pyrrolo[2,1-k][6,1,9,12]benzoxatriazacyclopentadecin-11(8H)-one, 19-chloro-18-fluoro-9,10,11a,12,13,14,16,21-octahydro-22-methoxy-,   4,6-ethanediylidene-8H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecine, 18-chloro-9,10,11,12,13,14,15,20-octahydro-21-methoxy-14-methyl-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecine, 19-chloro-8,9,10,11,12,13,14,15,16,21-decahydro-22-methoxy-15-methyl-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,9,12]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-,   12H-4,6-ethanediylidene-13,17-methanopyrimido[4,5-b][6,1,10,16]benzoxatriazacyclononadecin-12-one, 21-chloro-8,9,10,11,13,14,15,16,18,23-decahydro-25-methoxy-,   4,6-ethanediylidene-12H-pyrimido[4,5-b][6,1,10,13]benzoxatriazacyclohexadecin-12-one, 18-chloro-8,9,10,11,13,14,15,20-octahydro-21-methoxy-13,14-dimethyl-,   4,6-ethanediylidenepyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-15-ethyl-9,10,11,12,14,15,16,21-octahydro-22-methoxy-, or   4,6-ethanediylidenepyrimido[4,5-b][6,1,11,14]benzoxatriazacycloheptadecin-13(8H)-one, 19-chloro-9,10,11,12,14,15,16,21-octahydro-22-methoxy-14,15-dimethyl-,   
     
     
         8 . A compound according to any one of  claims 1  to  6  wherein the X 2  substituent is at position 2′, the R 1  substituent is at position 4′, the R 2  substituent is at position 5′, the R 3  substituent is at position 3 and the R 4  substituent at position 7 of the structure of formula (I). 
     
     
         9 . A kinase inhibitor of formula (I). 
     
     
         10 . A compound as claimed in any one of  claims 1  to  7  for use as a medicine. 
     
     
         11 . Use of a compound as claimed in any one of  claims 1  to  7  in the manufacture of a medicament for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer. 
     
     
         12 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, an effective kinase inhibitory amount of a compound as described in any one of the  claims 1  to  7 . 
     
     
         13 . A process for preparing a compound as claimed in  claims 1  to  7 , comprising
 a) coupling the 6-acetoxy-quinazolines of formula (II) with the suitable substituted anilines of formula (III) to furnish the intermediates of formula (IV), and deprotecting the intermediates of formula (IV) followed by ring closure under suitable conditions. 
 
       
         
           
           
               
               
           
         
       
       b) Deprotecting the intermediates of formula (IV b ) followed by formation of the corresponding ether using the appropriate aminated alcohol under standard conditions provides the intermediates of formula (XXVIII). Next, deprotection followed by ring closure provides the target compounds of formula (I′ b ). 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         14 . An intermediate of formula (III) 
       
         
           
           
               
               
           
         
       
       the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
 V represents hydrogen or a protective group preferably selected from the group consisting of methylcarbonyl, t-butyl, methyl, ethyl, benzyl or trialkylsilyl; 
 Y represents —C 3-9 alkyl-, —C 3-9 alkenyl-, —C 3-7 alkyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-, —C 3-7 alkenyl-CO—NH— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino-,
 —C 1-5 alkyl-oxy-C 1-5 alkyl-, —C 1-5 alkyl-NR 13 —C 1-5 alkyl-, —C 1-5 alkyl-NR 14 —CO—C 1-5 alkyl-, 
 —C 1-5 alkyl-CO—NR 15 —C 1-5 alkyl-, —C 1-6 alkyl-CO—NH—, —C 1-6 alkyl-NH—CO—, 
 —C 1-3 alkyl-NH—CS-Het 20 -, —C 1-3 alkyl-NH—CO-Het 20 -, C 1-2 alkyl-CO-Het 21 -CO—, 
 -Het 22 -CH 2 —CO—NH—C 1-3 alkyl-, —CO—NH—C 1-6 alkyl-, —NH—CO—C 1-6 alkyl-, 
 —CO—C 1-7 alkyl-, —C 1-7 alkyl-CO—, —C 1-6 alkyl-CO—C 1-6 alkyl-, 
 —CO-Het 20 -, —C 1-2 alkyl-NH—CO—CR 16 R 17 —NH—, —C 1-2 alkyl-CO—NH—CR 18 R 19 —CO—, 
 —C 1-2 alkyl-CO—NR 20 —C 1-3 alkyl-CO—, —C 1-2 alkyl-NR 21 —CH 2 —CO—NH—C 1-3 alkyl-, or 
 —NR 22 —CO—C 1-3 alkyl-NH—; 
 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 ,
 —NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 R 1  represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl-,
 halo-phenyl-carbonylamino-, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo; 
 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-,
 C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl-, C 2-6 alkynyl-, C 3-6 cycloalkyl-, 
 C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 , 
 C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-; 
 
 R 5  and R 6  are each independently selected from hydrogen or C 1-4 alkyl; 
 R 12  represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 18 -C 1-4 alkyl-,
 phenyl-C 1-4 alkyl-oxy-carbonyl-, Het 17 , C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or R 12  represents phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 13  represents hydrogen, C 1-4 alkyl, Het 13 , Het 14 -C 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 R 14  and R 15  are each independently selected from hydrogen, C 1-4 alkyl, Het 15 -C 1-4 alkyl- or C 1-4 alkyloxyC 1-4 alkyl-; 
 R 16  and R 17  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 18  and R 19  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 20  and R 22  each independently represents hydrogen or C 1-4 alkyl optionally substituted with hydroxy or C 1-4 alkyloxy; 
 R 21  represents hydrogen, C 1-4 alkyl, Het 23 -C 1-4 alkylcarbonyl- or
 R 21  represents mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-carbonyl- optionally substituted with hydroxy, pyrimidinyl, dimethylamine or C 1-4 alkyloxy; 
 
 Het 1  represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1  is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 
 Het 13  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 Het 14  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 allkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 15  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 16  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl; and 
 
 Het 17  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 Het 18  and Het 19  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, 
 hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 20 , Het 21  and Het 22  each independently represent a heterocycle selected from pyrrolidinyl, 2-pyrrolidinonyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from hydroxy,
 C 1-4 alkyl, hydroxy-C 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
 Ar 1 , Ar 2 , Ar 3 , Ar 4  and Ar 5  each independently represent phenyl optionally substituted with cyano, C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-,
 hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl. 
 
 
     
     
         15 . Use of an intermediate of formula (III) in the synthesis of a compound of formula (I). 
     
     
         16 . An intermediate of formula (XXX) 
       
         
           
           
               
               
           
         
       
       the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
 Y1 and Y2 each independently represent a C 1-5 alkyl, C 1-6 alkyl, CO—C 1-6 alkyl,
 CO—C 1-5 alkyl, Het 22 -CH 2 —CO, CO—CR 16 R 17 —NH—, Het 20 , CR 18 R 19 —CO—, 
 CH 2 —CO—NH—C 1-3 alkyl-, —C 1-2 alkyl-NR 21 —CH 2 —CO— or CO—C 1-3 alkyl-NH—; 
 
 X 1  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 11 ,
 —NR 11 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 ,
 —NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or —C 1-2 alkyl-; 
 
 R 1  represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl-,
 halo-phenyl-carbonylamino-, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo; 
 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-,
 C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl-, C 2-6 alkynyl-, C 3-6 cycloalkyl-, 
 C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 , 
 C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-; 
 
 R 3  represents hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with one or more substituents selected from halo, C 1-4 alkyloxy-, amino-, mono- or di(C 1-4 alkyl)amino-,
 C 1-4 alkyl-sulfonyl- or phenyl; 
 
 R 5  and R 6  are each independently selected from hydrogen or C 1-4 alkyl; 
 R 7  and R 8  are each independently selected from hydrogen, C 1-4 alkyl, Het 8 ,
 aminosulfonyl-, mono- or di (C 1-4 alkyl)-aminosulfonyl, hydroxy-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl-, hydroxycarbonyl-C 1-4 alkyl-, C 3-6 cycloalkyl, 
 Het 9 -carbonyl-C 1-4 alkyl-, Het 10 -carbonyl-, polyhydroxy-C 1-4 alkyl-, Het 11 -C 1-4 alkyl- or Ar 2 —C 1-4 alkyl-; 
 
 R 9  and R 10  are each independently selected from hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl,
 Het 4 , hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
 R 11  represents hydrogen, C 1-4 alkyl, Het 5 , Het 6 -C 1-4 alkyl-, C 2-4 alkenylcarbonyl-optionally substituted with Het 7 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-,
 C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 12  represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 17 , Het 18 -C 1-4 alkyl-,
 C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, 
 C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, 
 amino or C 1-4 alkyloxy-; 
 
 R 16  and R 17  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 18  and R 19  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 R 21  represents hydrogen, C 1-4 alkyl, Het 23 -C 1-4 alkylcarbonyl- or R 21  represents mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-carbonyl- optionally substituted with hydroxy, pyrimidinyl, dimethylamine or C 1-4 alkyloxy; 
 R 23  represents Ar 3 , Ar 4 —C 1-4 alkyl, C 1-4 alkyl, C 2-6 alkenyl optionally substituted with Het 12  or R 17  represents C 1-4 alkyl substituted with one or where possible two or more substituents selected from C 1-4 alkyloxy, hydroxy, halo, Het 2 , NR 7 R 8 ,
 NR 9 R 10 -carbonyl or Het 3 -carbonyl; 
 
 Het 1  represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1  is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 
 Het 2  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 2  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-, mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-, aminoC 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino-sulfonyl-, aminosulfonyl-; 
 
 Het 3 , Het 4  and Het 8  each independently represent a heterocycle selected from morpholinyl, piperazinyl, piperidinyl, furanyl, pyrazolyl, dioxolanyl, thiazolyl,
 oxazolyl, imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 3 , Het 4  or Het 8  is optionally substituted with one or where possible two or more substituents selected from hydroxy-, amino-, C 1-4 alkyl-, 
 C 3-6 cycloalkyl-C 1-4 alkyl-, aminosulfonyl-, mono- or di(C 1-4 alkyl)aminosulfonyl or amino-C 1-4 alkyl-; 
 
 Het 5  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 Het 6  and Het 7  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
 Het 9  and Het 10  each independently represent a heterocycle selected from furanyl,
 piperidinyl, morpholinyl, piperazinyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, 
 imidazolyl, isoxazolyl, oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 9  or Het 10  is optionally substituted C 1-4 alkyl, C 3-6 cycloalkyl-C 1-4 alkyl- or amino-C 1-4 alkyl-; 
 
 Het 11  represents a heterocycle selected from indolyl or 
 
       
         
           
           
               
               
           
         
         Het 12  represents a heterocycle selected from morpholinyl, piperazinyl, piperidinyl,
 pyrrolidinyl, thiomorpholinyl or dithianyl wherein said Het 12  is optionally substituted with one or where possible two or more substituents selected from hydroxy, halo, amino, C 1-4 alkyl-, hydroxy-C 1-4 alkyl-, C 1-4 alkyl-oxy-C 1-4 alkyl-, 
 hydroxy-C 1-4 alkyl-oxy-C 1-4 alkyl-, mono- or di(C 1-4 alkyl)amino- or mono- or di(C 1-4 alkyl)amino-C 1-4 alkyl-; 
 
         Het 16  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl; and 
 
         Het 17  represent a heterocycle selected from pyrrolidinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
         Het 18  and Het 19  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Het 20 , Het 21  and Het 22  each independently represent a heterocycle selected from pyrrolidinyl, 2-pyrrolidinonyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from hydroxy,
 C 1-4 alkyl, hydroxy-C 1-4 alkyl- or polyhydroxy-C 1-4 alkyl-; 
 
         Het 23  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, hydroxy-C 1-4 alkyl-,
 C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; 
 
         Ar 1 , Ar 3 , Ar 4  and Ar 5  each independently represent phenyl optionally substituted with cyano, C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-,
 hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl. 
 
       
     
     
         17 . An intermediate of formula (XXX) for use as a medicine. 
     
     
         18 . Use of an intermediate of formula (XXX) in the manufacture of a medicament for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer. 
     
     
         19 . Use of an intermediate of formula (XXX) in the synthesis of a compound of formula (I). 
     
     
         20 . An intermediate of formula (XXXIII) 
       
         
           
           
               
               
           
         
       
       the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
 m represents 1, 2, 3 or 4; 
 X 2  represents a direct bond, O, —O—C 1-2 alkyl-, CO, —CO—C 1-2 alkyl-, NR 12 ,
 —NR 12 —C 1-2 alkyl-, —CH 2 —, —O—N═CH— or C 1-2 alkyl; 
 
 Y 3  represents a C 1-5 alkyl, CO—C 1-5 alkyl or CO—CR 16 R 17 —NH— or C 1-5 alkyl-CO— optionally substituted with amino, mono- or di(C 1-4 alkyl)amino or C 1-4 alkyloxycarbonylamino; 
 R 1  represents hydrogen, cyano, halo, hydroxy, formyl, C 1-6 alkoxy-, C 1-6 alkyl-,
 halo-phenyl-carbonylamino-, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from hydroxy or halo; 
 
 R 2  represents hydrogen, cyano, halo, hydroxy, hydroxycarbonyl-, Het 16 -carbonyl-,
 C 1-4 alkyloxycarbonyl-, C 1-4 alkylcarbonyl-, aminocarbonyl-, mono- or di(C 1-4 alkyl)aminocarbonyl-, Het 1 , formyl, C 1-4 alkyl-, C 2-6 alkynyl-, C 3-6 cycloalkyl-, 
 C 3-6 cycloalkyloxy-, C 1-6 alkoxy-, Ar 5 , Ar 1 -oxy-, dihydroxyborane, 
 C 1-6 alkoxy- substituted with halo, 
 C 1-4 alkyl substituted with one or where possible two or more substituents selected from halo, hydroxy or NR 5 R 6 , 
 C 1-4 alkylcarbonyl- wherein said C 1-4 alkyl is optionally substituted with one or where possible two or more substituents selected from hydroxy or C 1-4 alkyl-oxy-; 
 
 R 3  represents hydrogen, C 1-4 alkyl, or C 1-4 alkyl substituted with one or more substituents selected from halo, C 1-4 alkyloxy-, amino-, mono- or di(C 1-4 alkyl)amino-,
 C 1-4 alkyl-sulfonyl- or phenyl; 
 
 R 5  and R 6  are each independently selected from hydrogen or C 1-4 alkyl; 
 R 12  represents hydrogen, C 1-4 alkyl, C 1-4 alkyl-oxy-carbonyl-, Het 18 -C 1-4 alkyl-,
 phenyl-C 1-4 alkyl-oxy-carbonyl-Het 17 , C 2-4 alkenylcarbonyl- optionally substituted with Het 19 -C 1-4 alkylaminocarbonyl-, C 2-4 alkenylsulfonyl-, C 1-4 alkyloxyC 1-4 alkyl- or phenyl optionally substituted with one or where possible two or more substituents selected from hydrogen, hydroxy, amino or C 1-4 alkyloxy-; 
 
 R 16  and R 17  each independently represents hydrogen or C 1-4 alkyl optionally substituted with phenyl, indolyl, methylsulfide, hydroxy, thiol, hydroxyphenyl,
 aminocarbonyl, hydroxycarbonyl, amine, imidazoyl or guanidino; 
 
 Het 1  represents a heterocycle selected from piperidinyl, morpholinyl, piperazinyl,
 furanyl, pyrazolyl, dioxolanyl, thiazolyl, oxazolyl, imidazolyl, isoxazolyl, 
 oxadiazolyl, pyridinyl or pyrrolidinyl wherein said Het 1  is optionally substituted with amino, C 1-4 alkyl, hydroxy-C 1-4 alkyl-, phenyl, phenyl-C 1-4 alkyl-, 
 C 1-4 alkyl-oxy-C 1-4 alkyl- mono- or di(C 1-4 alkyl)amino- or amino-carbonyl-; 
 
 Het 16  represent a heterocycle selected from morpholinyl, pyrrolidinyl, piperazinyl,
 1,3,2-dioxaborolane or piperidinyl wherein said heterocycle is optionally substituted with one or more substituents selected from C 1-4 alkyl; 
 
 Het 18  and Het 19  each independently represent a heterocycle selected from morpholinyl,
 pyrrolidinyl, piperazinyl or piperidinyl optionally substituted with one or where possible two or more substituents selected from C 1-4 alkyl, C 3-6 cycloalkyl, 
 hydroxy-C 1-4 alkyl-, C 1-4 alkyloxyC 1-4 alkyl or polyhydroxy-C 1-4 alkyl-; and 
 
 Ar 1  and Ar 5  each independently represent phenyl optionally substituted with cyano,
 C 1-4 alkylsulfonyl-, C 1-4 alkylsulfonylamino-, aminosulfonylamino-, 
 hydroxy-C 1-4 alkyl, aminosulfonyl-, hydroxy-, C 1-4 alkyloxy- or C 1-4 alkyl. 
 
 
     
     
         21 . An intermediate of formula (XXXIII) for use as a medicine. 
     
     
         22 . Use of an intermediate of formula (XXXIII) in the manufacture of a medicament for treating cell proliferative disorders such as atherosclerosis, restenosis and cancer. 
     
     
         23 . Use of an intermediate of formula (XXXIII) in the synthesis of a compound of formula (I).